Pds Biotechnology Corp (PDSB) - News Archive

Head and neck cancer, particularly associated with human papillomavirus (HPV) type 16, is emerging as a significant health concern, projected to dominate cases in the United States by the mid-2030s. PDS Biotech has init...

In a recent development, PDS Biotechnology Corporation (Nasdaq: PDSB), a cutting-edge player in the field of immunotherapy, has announced the granting of a nonstatutory stock option. The option allows for the purchase o...

: This article presents an analysis of recent developments in the treatment of locally advanced cervical cancer and head and neck cancer using PDS Biotechnology s Versamune HPV and chemoradiation therapy. Both diseases...

Recent advancements in cancer therapies continue to show promise in improving patient outcomes, particularly for challenging malignancies like melanoma. The latest data from PDS Biotech’s VERSATILE-002 Phase 2 clinical...

: The realm of cancer immunotherapy continues to evolve, with innovative approaches aiming to enhance patient outcomes. PDS Biotech s recent announcement regarding the updated data presentation from their VERSATILE-002...

PDS Biotech, a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat various cancers, has recently provided a promising data update from their ongoing VERSATILE-002 Phase 2 clinic...

In a groundbreaking development in the battle against head and neck cancer caused by the human papillomavirus 16 (HPV16), PDS Biotech has announced promising results from its VERSATILE-002 Phase 2 clinical trial. This p...

In an effort to address the unmet treatment needs of patients with recurrent or metastatic head and neck cancer, PDS Biotech recently organized a Key Opinion Leader (KOL) event to present and discuss encouraging updated...

PDS Biotechnology Grants Inducement Stock Options to New CFO Lars BoesgaardPRINCETON, N.J., Dec. 04, 2023 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company specializing in targeted i...